Envista Holdings Corp (NVST) Financial Ratio Screen

NYSE Healthcare United States USD 4358M
INSUFFICIENT / NOT IMPLEMENTED*
Automated financial screen · activity assessed separately
Envista Holdings Corp (NVST) needs additional financial data before the automated screen can be completed. One or more financial fields are missing; this is not a negative screening result.

Track NVST screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

NVST financial screening at a glance

INSUFFICIENT / NOT IMPLEMENTED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
28.1%
Pass vs 30%
Cash ratio
21.3%
Pass vs 30%
Receivables + cash
28.9%
Pass vs 30%
Impermissible income
N/A
Not available vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleMore financial data neededNo negative conclusion follows from missing data
FTSE/Yasaar-styleMore financial data neededNo negative conclusion follows from missing data
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Instruments & Supplies) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 28.1%
/ 30%
21.3%
/ 30%
28.9%
/ 30%
N/A INSUFFICIENT / NOT IMPLEMENTED*
FTSE 28.1%
/ 33%
21.3%
/ 33%
28.9%
/ 50%
N/A INSUFFICIENT / NOT IMPLEMENTED*

Financial Highlights

P/E Ratio
46.8
Forward: 16.3
EPS
$0.58
P/B Ratio
1.4
EV/EBITDA
12.0
EV: $4.9B
Revenue
$2.7B
Growth: 7.1%
Beta
0.9
Average volatility
Current Ratio
2.4

Profitability

Gross Margin 55.4%
Operating Margin 10.4%
Net Margin 3.3%
Return on Equity (ROE) 3.1%
Return on Assets (ROA) 3.2%

Cash Flow & Balance Sheet

Operating Cash Flow$276M
Free Cash Flow$230M
Total Debt$1.6B
Debt-to-Equity51.6
Current Ratio2.4
Total Assets$5.7B

Price & Trading

Last Close$27.44
50-Day MA$27.04
200-Day MA$25.08
Avg Volume2.8M
Beta0.9
52-Week Range
$18.77
$30.42

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-29 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About Envista Holdings Corp (NVST)

CEO
Mr. Eric D. Hammes
Employees
12,000
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 4358M
Currency
USD

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is Envista Holdings Corp (NVST) halal to invest in?

The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is Envista Holdings Corp's debt ratio?

Envista Holdings Corp's debt ratio is 28.1% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are Envista Holdings Corp's key financial metrics?

Envista Holdings Corp has a market capitalization of USD 4358M in its listing currency, trailing P/E ratio of 46.8, and revenue of $2.7B. The company maintains a gross margin of 55.4% and a net margin of 3.3%. Return on equity stands at 3.1%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.